JNJ continues to pay hefty integration charges on Synthes deal

More than 2½ years after it spent $21.3 billion on Synthes, Johnson & Johnson continues to take hefty charges on integrating the orthopedics company into its DePuy franchise.

Zimmer Holdings, Biomet, Covidien, DePuy Synthes, Johnson & Johnson, Medtronic

News Well, Mergers & Acquisitions

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1DfYzA9